From Acceptable Profit to Fair Return: Operational Benefit-Sharing Models for Induced Pluripotent Stem Cell Research...

There has been no previous study that specifies how benefit sharing could be delivered for biospecimens from low- and middle-income countries (LMICs) that enter high-value translational uses such as induced pluripotent stem cell (iPSC) research. Stakeholders endorse benefit sharing in principle, but the mechanisms that would make it deliverable, the actors who would guarantee it and the benefits that would count as fair remain undeveloped and contested and are further complicated by sample anonymization and by commercialization that crosses borders.

We conducted a framework analysis of qualitative data from the KACIY study, concerning the proposed reuse of stored, immortalized HapMap Project samples from the Yoruba community of Ibadan (YRI) for iPSC research. Data comprised key-informant interviews with six community advisory board (CAB) members and five United States genomic-research bioethicists, and two focus group discussions with twenty community members. We coded and charted the data against five axes: profit legitimacy, benefit types, delivery agents, timing of agreement, and feasibility constraints, and compared responses across the three stakeholder groups. Reporting follows the COREQ guidance.

We found that participants treated commercial profit as legitimate but treated benefit sharing as necessary to prevent extractive research and to preserve trust, and that they distinguished one-time compensation from ongoing benefit. Preferred benefits formed recurring bundles, which were subsidized access to resulting medicines and products, community infrastructure, capacity building and local co-investigation, recognition, and, for a minority, a proportional share of profits. Proposed guarantors included the national government and Ministry of Health, international bodies such as the World Health Organization, an independent third-party fiduciary, repositories acting through material transfer agreements, and local researchers and the CAB. Support for government custodianship was qualified by distrust. Bioethicists raised most of the feasibility constraints, which were funder rules, anonymization and cross-border enforcement. Participants held that terms should be agreed at the start of a project and that commercialization should be stated in the consent.

We translate this support into an architecture that can be implemented, comprising a tiered benefit-bundle menu with a guaranteed minimum and negotiated additions, an accountable guarantor model with escalation and an independent complaint channel, and contractual insertion points in material transfer agreements, data return requirements and product access commitments. Our study shows that benefit sharing for LMIC samples is best approached as a problem of implementation, and it specifies mechanisms that keep benefit sharing feasible, explicit and protective of community trust while avoiding the inflation of expectations.